Abstract:MicroRNAs have emerged as post-transcriptional regulators that are critically involved in the pathogenesis of a number of human cancers. Cdc42, one of the best characterized members of the Rho GTPase family, is found to be up-regulated in several types of human tumors, and has been implicated in cancer initiation and progression. In the present studies, we have identified miR-137 as a potential regulator of Cdc42 expression. A bioinformatics search revealed a target-site for miR-137 within the Cdc42 3’ UTR at nt 792-798, which is highly conserved across different species. Expression of miR-137 in colorectal cancer cell lines was found inversely correlated with Cdc42 expression. MiR-137 could significantly suppress Cdc42 3’ UTR luciferase-reporter activity, while this effect was not detectable when the putative target-site for miR-137 was mutated. Consistent with the results of reporter assay, ectopic expression of miR-137 reduced both mRNA and protein expression levels of Cdc42 and mimicked the effect of Cdc42 knockdown in inhibiting proliferation, inducing G1 cell cycle arrest, and blocking invasion of the colorectal cancer cells. Furthermore, expression of miR-137 suppressed the immediate downstream effector of Cdc42, PAK signaling in colorectal cancer cell lines. Our results suggest that miR-137 may have a tumor suppressor function by directly targeting the Rho GTPase Cdc42 to inhibit the proliferation and invasion activities of colorectal cancer cells. They raise an interesting possibility that Cdc42 activity and function can be controlled by microRNAs in addition to the classic regulators such as guanine nucleotide exchange factors and GTPase-activating proteins. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2036.

MiR-138 is a Potent Regulator of the Heterogenous MYC Transcript Population in Cancers.

H19-Derived Mir-675 Functions As An Oncogenic Microrna In Human Colorectal Cancers Through Targeting The Rb Tumor Suppressor

1069 MicroRNA-143 is a Potential Tumor Suppressor Targeting DNA Methyltransferases 3a in Colorectal Cancer

Microrna-138 Modulates Glioma Cell Growth, Apoptosis And Invasion Through The Suppression Of The Akt/Mtor Signalling Pathway By Targeting Creb1

miR‐145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC

MYC Protein Inhibits Transcription of the MicroRNA Cluster MC-let-7a-1∼let-7d Via Noncanonical E-box

Post‐transcriptional Regulation of the Tumor Suppressor Mir‐139‐5p and a Network of Mir‐139‐5p‐mediated Mrna Interactions in Colorectal Cancer

C-Myc-Regulated Mirna-92b Inhibits Expression of the E3 Ligase Fbxw7 in Colorectal Cancer

Mir‐137 Targets Cdc42 Expression, Induces Cell Cycle G1 Arrest and Inhibits Invasion in Colorectal Cancer Cells

Abstract 2036: MicroRNA-137 Reverse the Malignant Phenotypes of Colorectal Cancer Cells by Targeting Small GTPase Cdc42

Mir-320B Suppresses Cell Proliferation by Targeting C-Myc in Human Colorectal Cancer Cells.

c-Myc-regulated microRNAs modulate E2F1 expression

Mir-429 Modulates the Expression of C-Myc in Human Gastric Carcinoma Cells.

MicroRNA-142-3p Inhibits Tumorigenesis of Colorectal Cancer via Suppressing the Activation of Wnt Signaling by Directly Targeting to β-Catenin

MicroRNA-138 Inhibits Tumor Growth and Enhances Chemosensitivity in Human Cervical Cancer by Targeting H2AX

miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.

MiR-138 Induces Cell Cycle Arrest by Targeting Cyclin D3 in Hepatocellular Carcinoma.

MiR-139-5p: Promising Biomarker for Cancer

microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.

Mir-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2

Mir-193B Directly Targets STMN1 and Inhibits the Malignant Phenotype in Colorectal Cancer.